MedTrace Logo

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00006381 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in treating women who have metastatic breast cancer that has not responded to previous trastuzumab.

Conditions

Interventions

BIOLOGICAL

trastuzumab

DRUG

celecoxib

Sponsors & Collaborators

Principal Investigators

  • Chau T. Dang, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006381 on ClinicalTrials.gov